These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

175 related articles for article (PubMed ID: 28515251)

  • 1. New Treatment Options for the Management of Multiple Myeloma.
    Kumar SK
    J Natl Compr Canc Netw; 2017 May; 15(5S):709-712. PubMed ID: 28515251
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Autologous Stem Cell Transplantation in Multiple Myeloma in the Era of Novel Drug Induction: A Retrospective Single-Center Analysis.
    Thoennissen GB; Görlich D; Bacher U; Aufenberg T; Hüsken AC; Hansmeier AA; Evers G; Mikesch JH; Fritz F; Bokemeyer C; Müller-Tidow C; Stelljes M; Mesters RM; Krug U; Kropff MH; Thoennissen NH; Berdel WE
    Acta Haematol; 2017; 137(3):163-172. PubMed ID: 28399522
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [Induction therapy of transplant-eligible patients in multiple myeloma].
    Konishi J; Sunami K
    Nihon Rinsho; 2015 Jan; 73(1):90-4. PubMed ID: 25626311
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [Induction therapy and the role of stem cell transplantation in the treatment of myeloma multiplex in patients aged below 65 years].
    Stamatović D; Tukić L; Balint B
    Srp Arh Celok Lek; 2011 Dec; 139 Suppl 2():103-9. PubMed ID: 22352191
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Management of newly diagnosed symptomatic multiple myeloma: updated Mayo Stratification of Myeloma and Risk-Adapted Therapy (mSMART) consensus guidelines 2013.
    Mikhael JR; Dingli D; Roy V; Reeder CB; Buadi FK; Hayman SR; Dispenzieri A; Fonseca R; Sher T; Kyle RA; Lin Y; Russell SJ; Kumar S; Bergsagel PL; Zeldenrust SR; Leung N; Drake MT; Kapoor P; Ansell SM; Witzig TE; Lust JA; Dalton RJ; Gertz MA; Stewart AK; Rajkumar SV; Chanan-Khan A; Lacy MQ;
    Mayo Clin Proc; 2013 Apr; 88(4):360-76. PubMed ID: 23541011
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Management of multiple myeloma today.
    Anderson KC; Hamblin TJ; Traynor A
    Semin Hematol; 1999 Jan; 36(1 Suppl 3):3-8. PubMed ID: 9989482
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Optimizing therapy for transplant-eligible patients with newly diagnosed multiple myeloma.
    Moreau P; Giralt SA
    Leuk Res; 2012 Nov; 36 Suppl 1():S13-8. PubMed ID: 23176719
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Management of Transplant-Eligible Patients with Newly Diagnosed Multiple Myeloma.
    Laubach J; Kumar S
    Cancer Treat Res; 2016; 169():145-167. PubMed ID: 27696262
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Frontline treatment for transplant-eligible multiple myeloma: A 6474 patients network meta-analysis.
    Sekine L; Ziegelmann PK; Manica D; da Fonte Pithan C; Sosnoski M; Morais VD; Falcetta FS; Ribeiro MR; Salazar AP; Ribeiro RA
    Hematol Oncol; 2019 Feb; 37(1):62-74. PubMed ID: 30129104
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Frontline therapy in multiple myeloma: fast start for a long game.
    Patriarca F
    Lancet Haematol; 2019 Dec; 6(12):e600-e601. PubMed ID: 31624046
    [No Abstract]   [Full Text] [Related]  

  • 11. The role of transplant in multiple myeloma.
    Mei M; Somlo G
    J Natl Compr Canc Netw; 2014 Aug; 12(8):1131-8. PubMed ID: 25099445
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Maintenance therapy for multiple myeloma.
    McCarthy PL; Palumbo A
    Hematol Oncol Clin North Am; 2014 Oct; 28(5):839-59. PubMed ID: 25212886
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The role of high-dose chemotherapy in the treatment of multiple myeloma: a controversy.
    Kyle RA
    Ann Oncol; 2000; 11 Suppl 1():55-8. PubMed ID: 10707780
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Diagnosis and management guideline for multiple myeloma].
    Murakami H; Handa H; Saitoh T
    Nihon Rinsho; 2007 Dec; 65(12):2167-76. PubMed ID: 18069257
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Multiple myeloma - current issues and controversies.
    Kumar S
    Cancer Treat Rev; 2010 May; 36 Suppl 2():S3-11. PubMed ID: 20472186
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Timing of the high-dose therapy in the area of new drugs.
    Schmitt S; Bertsch U; Hose D; Goldschmidt H
    Srp Arh Celok Lek; 2011 Dec; 139 Suppl 2():90-4. PubMed ID: 22352189
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Bortezomib-based induction therapy followed by intravenous busulfan-melphalan as conditioning regimen for patients with newly diagnosed multiple myeloma.
    Blanes M; González JD; Lahuerta JJ; Ribas P; Lorenzo I; Boluda B; Sanz MA; de la Rubia J
    Leuk Lymphoma; 2015 Feb; 56(2):415-9. PubMed ID: 24828869
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Sustained disease control in transplant-ineligible patients: the role of continuous therapy.
    Palumbo A; Niesvizky R
    Leuk Res; 2012 Nov; 36 Suppl 1():S19-26. PubMed ID: 23176720
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Multiple myeloma treatment at relapse after autologous stem cell transplantation: A practical analysis.
    Malard F; Harousseau JL; Mohty M
    Cancer Treat Rev; 2017 Jan; 52():41-47. PubMed ID: 27888768
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Lenalidomide, adriamycin, dexamethasone for induction followed by stem-cell transplant in newly diagnosed myeloma.
    Knop S; Langer C; Engelhardt M; Mügge LO; Reichle A; Rösler W; Bassermann F; Hertenstein B; Kunitz A; Röllig C; Ostermann H; Schäfer-Eckart K; Ringhoffer M; Günther A; Junghanss C; Biersack H; Schreder M; Liebert A; Held S; Einsele H; Bargou RC
    Leukemia; 2017 Aug; 31(8):1816-1819. PubMed ID: 28439106
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 9.